Castle Biosciences (CSTL) Non-Current Assets (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Non-Current Assets data on file, last reported at $218.9 million in Q1 2026.

• Quarterly Non-Current Assets rose 43.71% year-over-year to $218.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $837.6 million (up 26.89% YoY) and the FY2025 annual result came in at $217.5 million, up 27.11% from the prior year.
• Non-Current Assets rose to $218.9 million in Q1 2026 per CSTL's latest filing, from $217.5 million in the prior quarter.
• The five-year high for Non-Current Assets was $218.9 million in Q1 2026, with the low at $108.0 million in Q1 2022.
• Average Non-Current Assets over 5 years is $168.3 million, with a median of $158.4 million recorded in 2022.
• Year-over-year, Non-Current Assets surged 912.79% in 2022 and slipped 6.39% in 2025.
• Castle Biosciences' Non-Current Assets stood at $155.0 million in 2022, then rose by 1.72% to $157.7 million in 2023, then grew by 8.48% to $171.1 million in 2024, then grew by 27.11% to $217.5 million in 2025, then climbed by 0.66% to $218.9 million in 2026.
• Business Quant data shows CSTL's Non-Current Assets at $218.9 million in Q1 2026, $217.5 million in Q4 2025, and $205.2 million in Q3 2025.